Labiana |
26 February
Labiana Health has been recognized as a success story on BME Growth by Bolsas y Mercados Españoles (BME), which highlights the company’s evolution since its IPO and its growth as a pharmaceutical group specializing in human and animal health, being the first veterinary pharmaceutical laboratory to be listed on the stock exchange in Spain.
Labiana |
19 February
Labiana Health has secured €37 million in syndicated financing and will execute a pre-emptive capital increase. The transaction enhances its credit profile and supports organic and inorganic growth.
Labiana |
9 September
In recent years, medicinal cannabis has attracted significant interest within the medical and scientific communities. The most studied and recognized compounds of this plant are tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which possess important therapeutic properties. However, terpenes—also present in cannabis—have begun to gain relevance in research due to their potential effects on the modulation and synergy with cannabinoids. This article explores the role of terpenes within the context of medicinal cannabis, highlighting their importance in the development of new treatments.
Labiana |
4 August
Labiana Health, the Spanish pharmaceutical group specializing in human and animal health, has published a communication through BME Growth, the Spanish alternative stock market where it is listed, disclosing an unaudited preliminary report on its consolidated financial results for the first half of the fiscal year in 2025.
Labiana |
26 June
Labiana, the pharmaceutical company specializing in animal and human health listed on BME Growth, is reinforcing its corporate governance with the appointment of Carme Hortalà as a new independent director and Juan Ortiz as a new proprietary director.
Labiana |
27 May
Labiana, the pharmaceutical company specializing in both animal and human health and listed on BME Growth, returns this year to the MedCap Forum—the key event for European small and mid-cap investors listed in Spain—to present its business model and expansion plan to interested investors.
